The Autonomous University of Querétaro (UAQ), represented by the rector, Teresa García Gasca, signed a collaboration agreement with the pharmaceutical group Neolpharma and Alpharma for the joint development of the QUIVAX 17.4 vaccine against SARS-CoV-2, a scientific project of this House of studies.
The UAQ and the pharmaceutical companies promised to develop at least one vaccine antigen against the virus that causes covid-19; perform the preclinical toxicological evaluation of the cellular and protective response of the drug; effecting the pharmaceutical development of the final product for administration to humans; as well as planning and developing clinical phases I and II, which correspond to the first stages of human trials.
The rector of the Alma Mater thanked the pharmaceutical company Neolpharma for the trust in the talent of the university researchers, led by Juan Joel Mosqueda Gualito, and stressed that there are good expectations for the antigen in which the UAQ Immunology and Vaccine Laboratory team works. .
The development of the vaccine against SARS-CoV-2 serves to show the authorities the scientific research capacity of the country’s public universities and request, once again, that Mexican projects be supported.
“Knowledge is sovereignty and our country will be sovereign until it can apply its own knowledge and stop depending on foreign technology and science. We have to have Mexican vaccines, “he said.
Likewise, the rector indicated that it is an opportunity to respond to the great support that society has given to this university initiative.
“That is why we have a multiplied commitment. It is a commitment to serve society by delivering a product that allows not only to face such a critical moment in the history of humanity, but to leave a sample of what we can do from now on, we as UAQ or any other institution that has research capacity. It is essential that Mexico pay attention to this. We owe it to the people. We want to deliver a real product to society, which allows us to have hope ”, said the professor.
In accordance with the agreement, Neolpharma and Alpharma will fully sponsor the phase I, phase II clinical studies and will develop the final product for administration in humans according to the applicable regulation, in addition to coordinating the procedures to present before the Federal Commission. for the Prevention against Sanitary Risks (Cofepris) the protocols of clinical trials.
The legal representative of Neolpharma and Alpharma, Efrén Ocampo López pointed out that the vaccine will undoubtedly bear the name of its origins and its university creators.
“When we realized that something so important was taking place here, we immediately went to work to support this research project. We lack a lot of work, we are eager to bring this to a final success and for our part we will add what is necessary, “said Ocampo López.
“We are really proud to join the UAQ team to go with this very important project for the country, because there are many days left to see the end of the covid-19 pandemic. The sovereignty of the country is here, it is being signed with this, “he added.
The pharmaceutical group Neolpharma is a Mexican corporation, incorporated on December 7, 2004, dedicated to the manufacture, elaboration, import, export, distribution and trade of all kinds of chemical, pharmaceutical, biological, medicinal and veterinary products; with plants located in Mexico City, Toluca and Ecatepec.